Mechanism and function of decreased FOXO1 in renal cell carcinoma

Journal of Surgical Oncology

Volumn 105, Issue 8, 2012, Pages 841-847

  Zhou, Libin ^a   Yin, Bingde ^a   Liu, Yongchao ^a   Hong, Yan ^a   Zhang, Changcun ^a   Fan, Jie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

FOXO1; miR 27a; proliferation; renal cell carcinoma

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR FKHR;

ARTICLE; CANCER GRADING; CANCER STAGING; CASE REPORT; CELL PROLIFERATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84861102150     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23013     Document Type: Article

References (34)

1. Chow WH, Devesa SS, Warren JL, et al.: Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-1631. (Pubitemid 29211773)
2. McKiernan JM, Buttyan R, Bander NH, et al.: The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 1999; 86: 492-497. (Pubitemid 29347412)
3. Maiese K, Chong ZZ, Shang YC, et al.: A "FOXO" in sight: Targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29: 395-418.
4. Wilson MS, Brosens JJ, Schwenen HD, et al.: FOXO and FOXM1 in cancer: The FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 2011; 12: 1256-1266.
5. Accili D, Arden KC,: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426. (Pubitemid 38610228)
6. Paik JH, Kollipara R, Chu G, et al.: FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323. (Pubitemid 46123514)
7. Lu H, Huang H,: FOXO1: A potential target for human diseases. Curr Drug Targets 2011; 12: 1235-1244.
8. Myatt SS, Wang J, Monteiro LJ, et al.: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010; 70: 367-377.
9. Goto T, Takano M, Albergaria A, et al.: Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008; 27: 9-19.
10. Guttilla IK, White BA,: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009; 284: 23204-23216.
11. Dong XY, Chen C, Sun X, et al.: FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 2006; 66: 6998-7006. (Pubitemid 44197675)
12. Gan B, Lim C, Chu G, et al.: FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 2010; 18: 472-484.
13. Kojima T, Shimazui T, Horie R, et al.: FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2010; 49: 379-389.
14. Zhang H, Pan Y, Zheng L, et al.: FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011; 71: 3257-3267.
15. Kyo S, Sakaguchi J, Kiyono T, et al.: Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth. Clin Cancer Res 2011; 17: 525-537.
16. Zhang H, Fang J, Yao D, et al.: Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells. Prostate 2010; 70: 1265-1273.
17. Gan L, Liu P, Lu H, et al.: Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death Differ 2009; 16: 1408-1417.
18. Daitoku H, Sakamaki JI, Fukamizu A,: Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011; 1813: 1954-1960.
19. Plas DR, Thompson CB,: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003; 278: 12361-12366. (Pubitemid 36800220)
20. Zanella F, Link W, Carnero A,: Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets 2010; 10: 135-146.
21. Huang H, Tindall DJ,: Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 2011; 1813: 1961-1964.
22. Fuhrman SA, Lasky LC, Limas C,: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663. (Pubitemid 13234762)
23. Livak KJ, Schmittgen TD,: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
24. Cindolo L, de la Taille A, Schips L, et al.: Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database. Urology 2005; 65: 681-686. (Pubitemid 40522999)
25. Kim TH, Jo SW, Lee YS, et al.: Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci 2009; 24: 468-473.
26. Maekawa T, Maniwa Y, Doi T, et al.: Expression and localization of FOXO1 in non-small cell lung cancer. Oncol Rep 2009; 22: 57-64.
27. Sourbier C, Lindner V, Lang H, et al.: The phosphoinositide 3-kinase/Akt pathway: A new target in human renal cell carcinoma therapy. Cancer Res 2006; 66: 5130-5142. (Pubitemid 43844935)
28. Zhang X, Tang N, Hadden TJ, et al.: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-1986.
29. Li M, Li J, Ding X, et al.: microRNA and cancer. AAPS J 2010; 12: 309-317.
30. Yang R, Schlehe B, Hemminki K, et al.: A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010; 121: 693-702.
31. Li X, Mertens-Talcott SU, Zhang S, et al.: MicroRNA-27a indirectly regulates estrogen receptor {alpha} expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology 2010; 151: 2462-2473.
32. Liu T, Tang H, Lang Y, et al.: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009; 273: 233-242.
33. Ma Y, Yu S, Zhao W, et al.: miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett 2010; 298: 150-158.
34. Chintharlapalli S, Papineni S, Abdelrahim M, et al.: Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta- olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 2009; 125: 1965-1974.